

Supplementary Table 5. CC-90010 detection in the CSF of one patient with medulloblastoma during cycle 1

Time since last dose, h*	Plasma concentration, ng/mL	CSF concentration, ng/mL	Ratio (CSF/plasma), %
0	178	11.8	6.6
0.5	487	—	NA
1	—	30.5	NA
2	651	43.1	6.6

CSF, cerebrospinal fluid; NA, not available.

*The patient was treated with CC-90010 35 mg on the weekly dosing schedule (2 days on/5 days off).